Genta, Inc.

Oral Gallium

Gallium compounds are bone-targeting agents that are potent inhibitors of bone breakdown and may be broadly useful for diseases associated with accelerated bone loss.

In March 2006, Emisphere entered into an exclusive worldwide licensing agreement with Genta, Inc. to develop an oral formulation of a gallium-containing compound. Under the agreement, the Company will utilize its Eligen^® Technology to supply a finished oral dosage from to Genta. Genta will be responsible for toxicology, clinical development, regulatory submissions and worldwide commercialization. In addition to royalties on net sales of the product, Genta has agreed to fund Emisphere's development activities and pay performance milestones related to the filing and approval of regulatory applications. An Investigational New Drug (IND) application was filed by Genta for gallium on July 31, 2007 and Genta announced that it commenced a Phase I study during the third quarter of 2007.